RBC Capital lowered the firm’s price target on Bausch + Lomb (BLCO) to $17 from $18 and keeps an Outperform rating on the shares ahead of its Q1 results. The focus is expected to fall on the company’s DED Rx drugs Miebo/Xiidra, the impact and resolution timelines of the IOL recall and potential tariff related headwinds following Reciprocal Tariffs announced by the U.S., the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLCO:
- Bausch + Lomb price target lowered to $15 from $17 at Stifel
- Bausch + Lomb Faces Growth Challenges Amid enVista Lens Recall and Increased Competition
- Bausch + Lomb cut to Equal Weight at Wells Fargo following enVista recall
- Bausch + Lomb downgraded to Equal Weight from Overweight at Wells Fargo
- Bausch + Lomb price reaction to recall ‘likely overdone,’ says RBC Capital